Positive initial results from personalized skin cancer vaccine

The new personalized vaccine, given in combination with a drug, has been successful in preventing the recurrence of skin cancer in patients during the trial.

This is being considered a major change in cancer treatment. This vaccine has been prepared by two pharmaceutical companies named Merck and Moderna. During the trial, this vaccine was given after surgery to patients suffering from high-risk melanoma (a type of skin cancer).

Initial results show that the vaccine increased the length of time patients remained cancer-free. However, how long this effect lasts is not yet clear.

Cancer experts have called it a major success, but have also advised caution, because the full results of the trial have not been released yet. Now independent experts will review and examine these results.

Even after the trial is over, the vaccine will be approved only if the regulators allow it. Only after this will it have to go through another approval process before it can be made available on Britain's NHS (National Health Service).

The vaccine, called Intismaren, was given in combination with a drug called Keytruda, which is an immunotherapy drug. Keytruda is already used to treat cancer.

The companies said that taking both the drug and the vaccine together significantly extended how long patients remained cancer-free compared to taking Keytruda alone.

Apart from this, the risk of the disease spreading to other organs reduced after the vaccine.

The Phase 3 trial included more than 1,000 patients with stage 2, stage 3 or stage 4 high-risk melanoma cancer.

Some of these patients had large tumors in a specific part of the body, while some had cancer that had spread to other parts of the body.

Merck and Moderna are calling it a personalized vaccine, which means the vaccine works by targeting an individual patient's tumor.

To create this new vaccine, scientists used mRNA technology. This technology was used for some COVID-19 vaccines.

This involves targeting specific mutations within cancer cells by surgically removing a small part of the patient's tumor and then sequencing its DNA.

That is, it is a personalized anti-cancer injection that is specific to the patient's tumor and instructs the immune system to recognize and attack any remaining tumor cells.

Both companies are testing other similar personalized vaccines for lung, bladder and kidney cancer.

Moderna Chief Executive Officer Stephane Bancel said that these findings are an important moment in the direction of cancer treatment. After this announcement, the shares of Moderna and Merck have risen sharply.

Cancer experts have also called this news positive, but they emphasize that these findings are still preliminary.

Dr Talisia Quallo, head of prevention and early detection at Cancer Research UK, said the research was promising, but the interim data had yet to be fully reviewed.

He added, “It is vital that research like this continues to be funded so that more people with cancer can have personalized treatment options that can help them live longer and better lives.”

"This is certainly good news for melanoma patients, but this study has broader implications. It proves the principle that personalized cancer vaccines can work," said Dr. Lennard Lee, a medical oncologist and associate professor at the University of Oxford.